Month: September 2020

14 September 2020Serabi Gold plc(“Serabi” or the “Company”)Exercise of share options and total voting rightsExercise of optionsThe Company announces that it has today issued 125,000 new Ordinary Shares following an exercise of options by a former director at an exercise price of 75 pence per new Ordinary Share. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.  Application is being made for the new Ordinary Shares to be admitted to trading on AIM on or around 18 September 2020, and they will also be listed on the TSX. The proceeds of the exercise amounted to £93,750.Total Voting RightsFollowing Admission, the Company’s issued share capital will consist of 59,084,551 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of...

MATTOON, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) — Consolidated Communications Holdings, Inc. (Nasdaq: CNSL) (“Consolidated”) announced today that its wholly-owned subsidiary, Consolidated Communications, Inc. (the “Issuer”), intends, subject to market and other customary conditions, to offer (the “Offering”) $1 billion in aggregate principal amount of Senior Secured Notes due 2028 (the “Notes”).Consolidated intends to use the net proceeds of the Offering to redeem all of the Issuer’s outstanding 6.50% Senior Notes due 2022, to repay a portion of outstanding borrowings under the Issuer’s existing credit facility and to pay related fees and expenses.The Notes will be offered in the United States to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the...

CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of Julie Carretero as Chief People Officer. In her new role, Ms. Carretero will assume leadership responsibilities for people initiatives, including talent acquisition and employee development, and will be a member of the Evelo Leadership Team.“We welcome Julie to Evelo’s Leadership Team at an exciting time as we progress to the next phase of our development, with up to six clinical readouts anticipated over the next 6-12 months,” said Simba Gill, Ph.D., Chief Executive Officer of Evelo. “Julie has successfully led and scaled organizations, and her extensive experience in strategic and operational...

If you want to retire at 60 but you don’t know how much money you need, this new report has the solution for you!Vitality Brink announced the launch of a new report on how to retire at 60 with $500K. The report covers the most important financial decisions you should make to achieve this goal. As people grow older, they start to wonder if their retirement nest egg will be enough for when they finally do retire. The newly launched report at Vitality Brink aims to help readers figure out if they can afford to retire at 60 with $500K.Determining how much is enough for retirement depends on many factors, such as a person’s lifestyle, plans for the future, and the number of years they will spend retired. According to Vitality Brink, in order to retire with $500K, you should eliminate your mortgage and move into a smaller home. In...

OTTAWA, Sept. 14, 2020 (GLOBE NEWSWIRE) — Leonovus Inc., (“Leonovus” or the “Company”) (TSXV: LTV) further to its news release of August 31, 2020, announces that it entered into a loan agreement with ten shareholders, including two directors, (the “Lenders”) for a secured loan in the principal amount of CAD$395,000 (the “Loan”). The Loan has a term of twelve months and bears interest at the rate of 8% per annum and can be paid down at any time without penalty.  The Loan is secured by a general security agreement.The Lenders received a bonus of 3,160,000 common shares (the “Bonus Shares”) of the Company at a deemed issue price of CAD$0.025 per share, representing 20% of the net amount of the total Loan. No commission or finder’s fee were paid in connection with the Loan. All bonus securities are subject to a hold period of four months...

CALGARY, Alberta, Sept. 14, 2020 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “Flyht”) announced today that the Company will participate in the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference, being held virtually on Thursday, September 17, 2020. Bill Tempany, Interim CEO, and Alana Forbes, CFO, will be holding one-on-one meetings with investors throughout the day.About FLYHT Aerospace Solutions Ltd.Flyht provides airlines with Actionable Intelligence to transform operational insight into immediate, quantifiable action, delivering industry leading solutions to improve aviation safety, efficiency and profitability. This unique capability is driven by Flyht’s patented aircraft certified hardware products including AFIRS™, a satcom aircraft interface device which...

 Ny ordre fra en amerikansk kunde. Højere aktivitetsniveau i Q4 2020 end tidligere forventet.  Tæt på optimal kapacitetsudnyttelse i det rumænske datterselskab.    Wirtek oplever et stærkt momentum, så i forlængelse af selskabets opjustering af resultatforventningerne den 8. august 2020 (selskabsmeddelelse nr. 119), finder bestyrelsen det nødvendigt at opjustere forventningerne igen. Wirtek har netop modtaget en ny ordre fra en af selskabets amerikanske kunder, som skal afvikles i indeværende år. Denne ordre får positiv indflydelse på Wirteks omsætning og resultat de kommende måneder. I tillæg ser vi en reduceret sandsynlighed for de COVID-19 risici, vi har indregnet i prognosen for helåret. Wirtek er således i en position, hvor vi forventer et fortsat højt aktivitetsniveau i resten af 2020 samt en kapacitetsudnyttelse tæt på optimal...

LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Jasbir S. Seehra, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 am ET.About Keros Therapeutics, Inc.Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding...

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo    Favorable safety and tolerability profileStrong efficacy profile with every two-week dosingStatistically significant improvements in markers of liver injury and key lipid parametersConference call and webcast scheduled for 8:30 am ET (5:30 am PT) todaySAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB) today announced positive topline results from its Phase 1b/2a trial with BIO89-100, an investigational FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH). All dose groups demonstrated significant reductions in liver fat at week 13, with relative reductions up to 60% versus baseline and up to 70% versus placebo, as measured by magnetic...